摘要
同步放化疗已成为局部晚期NSCLC的主要治疗方式,然而其治疗前是否行诱导化疗仍存在较大争议,治疗后行巩固化疗所获得的生存优势尚未达成共识.目前认为,在初始化疗剂量不足时推荐加用巩固化疗.伴随着放疗技术的发展及化疗药物的更新,同步放化疗有望为局部晚期NSCLC患者带来更好的生存获益.
Concurrent chemoradiation has been the main treatment of locally advanced non-small cell lung cancer （LA-NSCLC）.However, there is a controversy whether giving the induction chemotherapy before treatment.The survival advantage of consolidation chemotherapy doesn＆#39;t reach a consensus.When the dose of initial chemotherapy is insufficient, consolidation chemotherapy is necessary.With the development of radiotherapy and the renewal of the chemotherapy drugs, concurrent chemoradiation is expected to bring better survival benefit for the patients with LA-NSCLC.
出处
《国际肿瘤学杂志》
CAS
2015年第11期856-859,共4页
Journal of International Oncology
基金
重庆市大足区科技计划（DZKJ,2014ACC1047）
关键词
肺肿瘤
综合疗法
放射疗法
药物疗法
联合
同步放化疗
Lung neoplasms
Combined modality therapy
Radiotherapy
Drug therapy,combination
Concurrent chemoradiation
